ESMO: Academic Study Boosts Belief In TIL Therapies, Including Iovance’s Lifileucel
Company Has Begun Rolling Submission
Executive Summary
A new academic study presented at ESMO has provided the first Phase III data for tumor-infiltrating lymphocytes as a potential new therapeutic class, while industry leader Iovance looks set to have early-stage data for its TIL accepted by the US FDA.